These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35472176)

  • 21. Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study.
    Tamiya Y; Matsumoto S; Zenke Y; Yoh K; Ikeda T; Shibata Y; Kato T; Nishino K; Nakamura A; Furuya N; Miyamoto S; Kuyama S; Nomura S; Ikeno T; Udagawa H; Sugiyama E; Nosaki K; Izumi H; Sakai T; Hashimoto N; Goto K
    Lung Cancer; 2023 Feb; 176():103-111. PubMed ID: 36634571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
    Arbour KC; Rizvi H; Plodkowski AJ; Hellmann MD; Knezevic A; Heller G; Yu HA; Ladanyi M; Kris MG; Arcila ME; Rudin CM; Lito P; Riely GJ
    Clin Cancer Res; 2021 Apr; 27(8):2209-2215. PubMed ID: 33558425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
    van de Haar J; Ma X; Ooft SN; van der Helm PW; Hoes LR; Mainardi S; Pinato DJ; Sun K; Salvatore L; Tortora G; Zurlo IV; Leo S; Giampieri R; Berardi R; Gelsomino F; Merz V; Mazzuca F; Antonuzzo L; Rosati G; Stavraka C; Ross P; Rodriquenz MG; Pavarana M; Messina C; Iveson T; Zoratto F; Thomas A; Fenocchio E; Ratti M; Depetris I; Cergnul M; Morelli C; Libertini M; Parisi A; De Tursi M; Zanaletti N; Garrone O; Graham J; Longarini R; Gobba SM; Petrillo A; Tamburini E; La Verde N; Petrelli F; Ricci V; Wessels LFA; Ghidini M; Cortellini A; Voest EE; Valeri N
    Nat Med; 2023 Mar; 29(3):605-614. PubMed ID: 36864254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).
    Bruera G; Cannita K; Di Giacomo D; Lamy A; Frébourg T; Sabourin JC; Tosi M; Alesse E; Ficorella C; Ricevuto E
    BMC Med; 2013 Mar; 11():59. PubMed ID: 23497191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAS mutated Non-Small Lung Carcinoma: A Real World Context from the Indian subcontinent.
    Batra U; Nathany S; Sharma M; Bp A; Jose JT; Singh H; Mattoo S; Mehta A
    Cancer Med; 2023 Feb; 12(3):2869-2874. PubMed ID: 36069080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer.
    Tan ES; Fan W; Knepper TC; Schell MJ; Sahin IH; Fleming JB; Xie H
    Target Oncol; 2022 Jul; 17(4):483-492. PubMed ID: 35767139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer.
    Huang CW; Tsai HL; Chen YT; Huang CM; Ma CJ; Lu CY; Kuo CH; Wu DC; Chai CY; Wang JY
    BMC Cancer; 2013 Dec; 13():599. PubMed ID: 24330663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS Mutation: Characterization and Its Impact on Survival Outcome of Patients with Metastatic Colorectal Cancer.
    Damit D; Patnaik R; Chaw LL; Lu SK; Telisinghe PU; Lu ZH; Kok K; Ming LC; Lim YC
    Front Biosci (Landmark Ed); 2022 Jul; 27(7):213. PubMed ID: 35866409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.
    Bruera G; Cannita K; Di Giacomo D; Lamy A; Troncone G; Dal Mas A; Coletti G; Frébourg T; Sabourin JC; Tosi M; Ficorella C; Ricevuto E
    BMC Med; 2012 Nov; 10():135. PubMed ID: 23136868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.
    Mazzaschi G; Perrone F; Minari R; Verzè M; Azzoni C; Bottarelli L; Pluchino M; Armillotta MP; Ubaldi A; Altimari A; Gruppioni E; Sperandi F; Andrini E; Guaitoli G; Bettelli S; Longo L; Bertolini F; Barbieri F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Gnetti L; Tiseo M;
    Clin Lung Cancer; 2022 Nov; 23(7):e478-e488. PubMed ID: 36002369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
    Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
    PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen.
    Bruera G; Cannita K; Giordano AV; Vicentini R; Ficorella C; Ricevuto E
    Int J Oncol; 2014 Jun; 44(6):1820-30. PubMed ID: 24715238
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Jones GD; Caso R; Tan KS; Mastrogiacomo B; Sanchez-Vega F; Liu Y; Connolly JG; Murciano-Goroff YR; Bott MJ; Adusumilli PS; Molena D; Rocco G; Rusch VW; Sihag S; Misale S; Yaeger R; Drilon A; Arbour KC; Riely GJ; Rosen N; Lito P; Zhang H; Lyden DC; Rudin CM; Jones DR; Li BT; Isbell JM
    Clin Cancer Res; 2021 May; 27(9):2604-2612. PubMed ID: 33593884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrating
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
    World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
    Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
    Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liquid biopsy for
    Güttlein L; Luca MR; Esteso F; Fresno C; Mariani J; Otero Pizarro M; Brest E; Starapoli S; Kreimberg K; Teves P; Mendoza Bertelli A; R Girotti M; Salanova R; O'Connor JM
    Future Oncol; 2022 Sep; 18(29):3277-3287. PubMed ID: 36004810
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.
    Laurent-Puig P; Pekin D; Normand C; Kotsopoulos SK; Nizard P; Perez-Toralla K; Rowell R; Olson J; Srinivasan P; Le Corre D; Hor T; El Harrak Z; Li X; Link DR; Bouché O; Emile JF; Landi B; Boige V; Hutchison JB; Taly V
    Clin Cancer Res; 2015 Mar; 21(5):1087-97. PubMed ID: 25248381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
    Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
    J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.
    Strickler JH; Yoshino T; Stevinson K; Eichinger CS; Giannopoulou C; Rehn M; Modest DP
    Oncologist; 2023 Nov; 28(11):e981-e994. PubMed ID: 37432264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.